VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 335 filers reported holding VALEANT PHARMACEUTICALS INTL in Q1 2017. The put-call ratio across all filers is 1.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $4,531,000 | +519.8% | 194,800 | +324.4% | 0.02% | +566.7% |
| Q1 2018 | $731,000 | -90.5% | 45,900 | -87.5% | 0.00% | -90.9% |
| Q4 2017 | $7,708,000 | +125.1% | 368,617 | +53.9% | 0.03% | +120.0% |
| Q3 2017 | $3,425,000 | -74.3% | 239,525 | -68.8% | 0.02% | -75.0% |
| Q2 2017 | $13,346,000 | +23314.0% | 768,929 | +14977.0% | 0.06% | – |
| Q1 2017 | $57,000 | -94.4% | 5,100 | -92.7% | 0.00% | -100.0% |
| Q4 2016 | $1,009,000 | -90.3% | 69,500 | -83.7% | 0.01% | -90.4% |
| Q3 2016 | $10,411,000 | +177.8% | 425,100 | +127.5% | 0.05% | +173.7% |
| Q2 2016 | $3,748,000 | +4527.2% | 186,884 | +5928.5% | 0.02% | – |
| Q1 2016 | $81,000 | -72.4% | 3,100 | +6.9% | 0.00% | -100.0% |
| Q4 2015 | $293,000 | -25.1% | 2,900 | +31.8% | 0.00% | 0.0% |
| Q3 2015 | $391,000 | -34.7% | 2,200 | -18.5% | 0.00% | -33.3% |
| Q2 2015 | $599,000 | – | 2,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |